South Korea caps semaglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 21 of 33 of this archive, newest first.
Efficacy was never the question in this appraisal. Duration of treatment was.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the analysis, not from a warning notice.
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.